


Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underrecognized health needs. In addition to our purpose-built products, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous thromboembolism and beyond. We are just getting started.

A mission, a plan, and crisp execution producing sustained growth

- ▶ **Purpose Built, Highly Differentiated Solutions** designed to solve specific problems
- ▶ **Leading, Differentiated Data** (6 major studies, including 2 ongoing RCTs)**
- ▶ **BIG, Growing, and Efficient Commercial Team** of over 280+ territories
- ▶ **Robust Product Pipeline** (10 products launched 2021-2022)***
- ▶ **Large Markets, Lot of Runway** (\$5.8B in US VTE alone, <6% penetrated)*
- ▶ **Efficient Procedures, Favorable Economics** driven by limited hospital resources, avoiding ICU stay, and reducing total length of stay

Large US total addressable market totaling ~\$8B across 5 disease states




FINANCIAL PROFILE

Robust quarterly revenue growth with gross margins of >80%

REVENUES

(LAST 8 QUARTERS, \$ IN MILLIONS)



*Based on third party data and Inari management estimates

**FLARE, FLASH, FLAME, CLOUT, PEERLESS, DEFIANCE

*** Products launched 2021: Triever20 Curve catheter, FlowTriever2 catheter, FlowStasis, FlowSaver, Triever24 Flex catheter; Products launched 2022: ClotTriever BOLD catheter, Intri24 sheath, Protrieve sheath, InThrive system, Triever Gen 4 catheters

1. "Pulmonary Embolism in 2017: Increasing Options for Increasing Incidence", National Center for Biotechnology Information, May 2017.

2. Picart, et al. Predictors of residual pulmonary vascular obstruction after pulmonary embolism: Results from a prospective cohort study. Thrombosis Research, 2020.

3. Dzilkowska-Diduch, et al. The post-pulmonary syndrome - results of echocardiographic driven follow up after acute pulmonary embolism. Thrombosis Research, 2020.

4. Sista AK, et al. Vasc Med. 2017 Feb;22(1):37-43

5. Kahn, Susan R. Hematology Am Soc Hematol Educ Program. 2016 Dec 2; 2016(1): 413-418

6. Young et al., Post-treatment residual thrombus increases the risk of recurrent deep vein thrombosis and mortality. J Thromb Haemost 2006; 4: 1919-24.

CONTACT INFORMATION

📍 6001 Oak Canyon, Ste.100, Irvine, CA 92618, USA
📍 Messeplatz 10, 4058 Basel, Switzerland

@ info@inarimedical.com

🌐 inarimedical.com

(NASDAQ: NARI)